

# Peripartum Cardiomyopathy

## A Review

Anirban Bhattacharyya, MD  
Sukhdeep Singh Basra, MD,  
MPH  
Priyanka Sen, BS  
Biswajit Kar, MD

**Key words:** Cardiac output; cardiomyopathies/diagnosis/epidemiology/etiology/therapy; cardiomyopathy, dilated/physiopathology/prevention & control; cardiomyopathy, peripartum; heart failure/diagnosis/etiology/physiopathology/therapy; lactation/blood; postpartum period; pregnancy complications, cardiovascular/diagnosis/epidemiology/etiology/therapy; pregnancy, multiple; pregnancy trimester, third; prognosis; puerperal disorders; ventricular dysfunction, left

**From:** School of Public Health, The University of Texas (Dr. Bhattacharyya); Department of Internal Medicine, Baylor College of Medicine (Dr. Basra); Medical Student, Baylor College of Medicine (Ms Sen); and Divisions of Cardiology & Cardiothoracic Surgery (Dr. Kar), Texas Heart Institute at St. Luke's Episcopal Hospital and Baylor College of Medicine; Houston, Texas 77030

**Address for reprints:** Biswajit Kar, MD, Division of Cardiology, Texas Heart Institute at St. Luke's Episcopal Hospital and Baylor College of Medicine, 6720 Bertner Ave., C355M, Houston, TX 77030

**E-mail:** kar@bcm.tmc.edu

© 2012 by the Texas Heart® Institute, Houston

Peripartum cardiomyopathy is idiopathic heart failure occurring in the absence of any determinable heart disease during the last month of pregnancy or the first 5 months postpartum. The incidence varies worldwide but is high in developing nations; the cause of the disease might be a combination of environmental and genetic factors. Diagnostic echocardiographic criteria include left ventricular ejection fraction  $<0.45$  or M-mode fractional shortening  $<30\%$  (or both) and end-diastolic dimension  $>2.7$  cm/m<sup>2</sup>. Electrocardiography, magnetic resonance imaging, endomyocardial biopsy, and cardiac catheterization aid in the diagnosis and management of peripartum cardiomyopathy. Cardiac protein assays can also be useful, as suggested by reports of high levels of NT-proBNP, cardiac troponin, tumor necrosis factor- $\alpha$ , interleukin-6, interferon- $\gamma$ , and C-reactive protein in peripartum cardiomyopathy. The prevalence of mutations associated with familial dilated-cardiomyopathy genes in patients with peripartum cardiomyopathy suggests an overlap in the clinical spectrum of these 2 diseases.

Treatment for peripartum cardiomyopathy includes conventional pharmacologic heart-failure therapies—principally diuretics, angiotensin-converting enzyme inhibitors, vasodilators, digoxin,  $\beta$ -blockers, anticoagulants, and peripartum cardiomyopathy-targeted therapies. Therapeutic decisions are influenced by drug-safety profiles during pregnancy and lactation. Mechanical support and transplantation might be necessary in severe cases. Targeted therapies (such as intravenous immunoglobulin, pentoxifylline, and bromocriptine) have shown promise in small trials but require further evaluation. Fortunately, despite a mortality rate of up to 10% and a high risk of relapse in subsequent pregnancies, many patients with peripartum cardiomyopathy recover within 3 to 6 months of disease onset. (*Tex Heart Inst J* 2012;39(1):8-16)

**P**eripartum cardiomyopathy is a rare, serious disease of late pregnancy or early puerperium. In 1971, Demakis and colleagues<sup>1</sup> first defined peripartum cardiomyopathy as idiopathic heart failure (HF) occurring in the absence of any determinable heart disease in the last month of pregnancy or during the first 5 months postpartum. Later, to prevent over-reporting, echocardiographic criteria (Table I) were added to this definition.<sup>2</sup>

Peripartum cardiomyopathy is characterized by its rapid clinical course<sup>3</sup> and a probability for spontaneous recovery.<sup>4</sup> It is of interest that early and late presentations of heart failure in pregnancy appear to have similar demographics and outcomes,<sup>5</sup> for this suggests that the same disease process underlies the 2 presentations. This has led to a call to review the existing definition of peripartum cardiomyopathy to include patients who currently do not fit those strict criteria.<sup>6</sup>

### Epidemiology

Data from population-based and single-center studies provide the best available estimates of the incidence of peripartum cardiomyopathy. The reported incidence fluctuates globally but is higher in developing countries. For example, the incidence in Nigeria<sup>7</sup> (1%) or Haiti<sup>8</sup> (0.33%) surpasses that in more developed countries, such as South Africa<sup>9</sup> (0.1%) or the United States (1:3,000–4,000 deliveries).<sup>4</sup> Environmental and genetic factors, differences in cultural practices, and standards of perinatal care may account for this regional disparity.

## Cause

Specific causal factors for peripartum cardiomyopathy have not yet been identified. Black race,<sup>10</sup> multiparity,<sup>11</sup> maternal age >30 years,<sup>12</sup> twin pregnancies,<sup>5</sup> and history of hypertension, preeclampsia, and eclampsia are each associated with a higher incidence of peripartum cardiomyopathy, but no causal association has been shown. Recent evidence, though, suggests that inflammatory and genetic mechanisms are at work in peripartum cardiomyopathy.

### Role of Inflammation in Peripartum Cardiomyopathy

Reports of high concentrations of tumor necrosis factor- $\alpha$  (TNF $\alpha$ ), interferon- $\gamma$ , interleukin-6, C-reactive protein (CRP), and Fas/apoptosis antigen 1 (Apo-1) in peripartum cardiomyopathy<sup>13</sup> suggest an underlying inflammatory process for the pathophysiologic development of peripartum cardiomyopathy. Physiologic changes during pregnancy usually boost maternal antioxidant defense mechanisms.<sup>14</sup> However, peripartum cardiomyopathy patients exhibit high levels of oxidative stress (for example, increased levels of oxidized low-density lipoprotein).<sup>3</sup> In murine cardiomyocytes, deletion of the signal transducer and activator of transcription 3 (stat3) gene responsible for protection from oxidative stress causes peripartum cardiomyopathy in a dose-dependent fashion.<sup>3</sup> In brief, stat3 deletion leads to overexpression of cathepsin D, which cleaves prolactin into its 16-kDa active form, thereby enhancing the antiangiogenic and pro-apoptotic properties of prolactin that are so instrumental in destroying cardiac and vascular tissues.<sup>3</sup> Reports of elevated levels of Fas/Apo-1 at baseline predicting death in human beings support this hypothesis.<sup>13</sup>

### Myocarditis

The existing literature indicates that most patients with peripartum cardiomyopathy have myocardial inflam-

mation. Accordingly, in this review, we use the term myocarditis to refer to that inflammation. We emphasize, however, that the cause of the inflammation remains obscure.

The lines of evidence for and against a role for myocarditis in the causation of peripartum cardiomyopathy are tenuous. On the one hand, cardiomyocyte necrosis after interstitial and perivascular inflammation was first identified in peripartum cardiomyopathy patients,<sup>15</sup> the reported incidence of myocarditis in peripartum cardiomyopathy ranges from 29% to 100%,<sup>16</sup> and at least 1 group has reported viral genomes in 31% of peripartum cardiomyopathy patients with interstitial inflammation.<sup>17</sup> On the other hand, the rates of myocarditis among peripartum cardiomyopathy patients are not universally high.<sup>18,19</sup> Why the reported rates of active myocarditis in peripartum cardiomyopathy vary so widely is unknown. Confounding factors may include the likelihood that endomyocardial biopsy detects myocarditis when it is performed closer to the onset of peripartum cardiomyopathy,<sup>18</sup> the absence of magnetic resonance imaging (MRI) guidance in some of the endomyocardial biopsy studies, the performance of endomyocardial biopsy at the wrong site, and the misdiagnosis of another type of heart failure as peripartum cardiomyopathy.<sup>18,20</sup>

### Fetal Chimerism

Fetal cells escaping into the maternal circulation during pregnancy are generally destroyed by the maternal immune system.<sup>21</sup> However, some of these chimeric cells with weak paternal haplotype may somehow evade the weakened maternal immune system during pregnancy and settle in the maternal heart, where they reside until they trigger a postpartum response by the normalized immune system.<sup>22</sup> High titers of antibodies directed against cardiac myosin heavy chains have been identified in the sera of peripartum cardiomyopathy patients but not in patients with idiopathic dilated cardiomyopathy (DCM) or in healthy individuals.<sup>21</sup> This could explain the higher incidence of peripartum cardiomyopathy in twin pregnancies and recurrences in subsequent pregnancies.<sup>16</sup> Meanwhile, the causal relationship, if any, between these antibodies and peripartum cardiomyopathy remains unclear.

### Genetic Associations

The prevalence of mutations associated with familial dilated cardiomyopathy genes in patients with peripartum cardiomyopathy suggests that there may be an overlap in the clinical spectrum of these two diseases. van Spaendonck-Zwarts and colleagues<sup>23</sup> identified 5 cases of peripartum cardiomyopathy among 90 cases of familial DCM. They also identified 3 patients with peripartum cardiomyopathy who had an incomplete recovery and had first-degree DCM relatives, including 1 patient who had a *c.149A>G*, *p.Gln50Arg* mutation. Other investi-

**TABLE I.** Current Diagnostic Criteria for Peripartum Cardiomyopathy

1. Development of heart failure in last month of pregnancy or 5 months postpartum
2. Absence of preexisting heart disease
3. Indeterminant cause
4. Echocardiographic findings (a, together with b or c; or all of these)
  - a. Left ventricular end-diastolic dimension >2.7 cm/m<sup>2</sup>
  - b. M-mode fractional shortening <30%
  - c. Left ventricular ejection fraction <0.45

Adapted from Demakis JG, Rahimtoola SH. Peripartum cardiomyopathy. *Circulation* 1971;44(5):964-8<sup>1</sup>; and from Manolio TA, Baughman KL, Rodeheffer R, Pearson TA, Bristow JD, Michels VV, et al. Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop). *Am J Cardiol* 1992;69(17):1458-66.<sup>2</sup>

gators identified familial mutations in *MYH7*, *SCN5A*, and *PSEN2* genes and sporadic mutations in *MYH6* and *TNNT2* DCM genes of peripartum cardiomyopathy patients.<sup>24</sup> If these findings represent a true association between cardiac gene mutations and peripartum cardiomyopathy, they may pave the way to genetic screening tests for peripartum cardiomyopathy.

## Clinical Presentation and Diagnosis

Typically, peripartum cardiomyopathy occurs in the first 4 months postpartum; fewer than 10% of cases occur prepartum.<sup>6,25</sup> Common symptoms include dyspnea, cough, orthopnea, hemoptysis, and paroxysmal nocturnal dyspnea. Most affected patients have New York Heart Association (NYHA) class III or IV function.<sup>16</sup> Additional symptoms include nonspecific fatigue, malaise, palpitations, chest and abdominal discomfort, and postural hypotension.<sup>16</sup> Diagnosis requires a high degree of suspicion, because symptoms of peripartum cardiomyopathy can be confused with physiologic changes associated with advanced pregnancy. Common signs of peripartum cardiomyopathy include displacement of the apical impulse, presence of  $S_3$ , and evidence of mitral or tricuspid regurgitation. Engorgement of the neck veins, pulmonary crepitations, hepatomegaly, and pedal edema may also be present.<sup>16,25</sup>

Peripartum cardiomyopathy is diagnosed only when the following criteria are met: left ventricular ejection fraction (LVEF)  $<0.45$  or M-mode fractional shortening  $<30\%$  (or both) and end-diastolic dimension  $>2.7$  cm/m<sup>2</sup> (Table I).<sup>2</sup> The differential diagnosis includes accelerated hypertension, diastolic dysfunction, systemic infection, pulmonary embolus, and obstetric complications such as preeclampsia, eclampsia, and amniotic fluid embolism. Diagnosis and postpartum monitoring are facilitated by electrocardiography, echocardiography, MRI, endomyocardial biopsy, and cardiac protein assays.

### Electrocardiography

No pathognomic changes in electrocardiograms have been identified for peripartum cardiomyopathy. The most commonly seen electrocardiographic changes are left ventricular (LV) hypertrophy and ST-T wave abnormalities.<sup>26</sup> Complications such as atrial fibrillation and flutter, Q waves in anteroseptal leads, prolonged PR and QRS intervals, and bundle branch blocks are also seen.

### Doppler Echocardiography

Echocardiography is essential for diagnosis (Table I). Its effectiveness obviates the need for invasive cardiac catheterization.<sup>16</sup> Common echocardiographic findings include globally decreased contractility and LV enlargement without hypertrophy.<sup>25</sup> Echocardiography is also useful for diagnosing mural thrombus, mitral or tricuspid regurgitation, and pericardial effusion.<sup>6</sup> Follow-up

studies have revealed that higher LVEF at presentation portends better cure rates and shorter recovery times.<sup>27</sup> Moreover, patients with high initial LVEF are less likely to experience relapse during a subsequent pregnancy.<sup>28</sup> Prompt echocardiography in all symptomatic pregnant patients can help to reveal patients with undiagnosed peripartum cardiomyopathy earlier in the course of the disease, thereby leading to earlier institution of care and to improvement of outcomes. Dobutamine stress echocardiography can determine the contractile reserve of patients with a history of peripartum cardiomyopathy and can help identify those at risk of relapse.<sup>28</sup> Follow-up echocardiography to monitor progress should be done at discharge from the hospital, at 6 weeks and 6 months postpartum, and annually thereafter.<sup>6</sup>

### Magnetic Resonance Imaging

Cardiac MRI using  $T_2$ -weighted spin echo sequences enables the precise diagnosis of myocarditis, necrosis, and LV thrombi, and it yields accurate measurements of ventricular volumes. In addition, MRI helps identify endomyocardial biopsy sites. Injection of gadolinium as the contrast agent is best avoided prepartum, because gadolinium can cross the placenta.<sup>29,30</sup>

### Endomyocardial Biopsy

Endomyocardial biopsy is a highly specific technique for diagnosing myocarditis.<sup>31</sup> However, its invasive nature, coupled with the varying incidence of myocarditis in peripartum cardiomyopathy, precludes its use as a first-line diagnostic tool.<sup>16</sup> Biopsy under MRI guidance improves accuracy and can be followed up with polymerase chain reaction analysis of biopsy DNA extracts for viral assays or immunohistochemical staining for autoantibody assays. Endomyocardial biopsy might be considered when myocarditis is strongly suspected or no improvement is seen after 2 weeks of heart-failure therapy.<sup>16</sup>

### Cardiac Protein Assays

Cardiac protein assays show promise for diagnosis and postpartum disease monitoring. In one series of 38 patients,<sup>32</sup> N-terminal proBNP (NT-proBNP) levels were significantly higher in peripartum cardiomyopathy patients than in healthy postpartum control participants ( $P < 0.0001$ ). In a larger prospective trial of 106 patients,<sup>33</sup> high cardiac troponin T levels ( $>0.4$  ng/mL) within 2 weeks of peripartum cardiomyopathy onset significantly predicted smaller LVEF and persistent LV dysfunction at 6-month follow-up ( $P < 0.001$ ). Although cardiac protein assays are not yet part of the standard management protocol for peripartum cardiomyopathy, their clinical usefulness continues to be evaluated.

### Other Tests

Cardiac catheterization has been superseded by non-invasive imaging techniques. It is, however, still needed

to perform endomyocardial biopsies, and to evaluate the hemodynamic profile when noninvasive techniques may not be accurate.<sup>16</sup>

## Management

### Heart Failure Therapy

Because of its setting in the peripartum period, peripartum cardiomyopathy requires a well-coordinated multidisciplinary approach to management that involves cardiovascular medicine, obstetrics, immunology, pathology, and other specialties for the management of complications. The management of peripartum cardiomyopathy is similar to that of other types of heart failure. The first aim is to improve symptoms through conventional pharmacologic therapies and, if necessary, nonpharmacologic therapies. The second aim is to effect a cure through the administration of targeted therapies.

Oxygen, diuretics, and angiotensin-blocking drugs are used for the acute management of peripartum cardiomyopathy.<sup>34</sup> Regardless of the drugs used, their safety profiles during pregnancy or lactation must be considered (Table II), and their side effects must be closely monitored and managed.

**Diuretics.** Diuretics reduce preload and treat pulmonary congestion or peripheral edema. Both hydrochlorothiazide and furosemide are safe during pregnancy and lactation.<sup>35</sup> However, diuretic-induced dehydration can cause uterine hypoperfusion and maternal metabolic acidosis, so bicarbonate monitoring and management with acetazolamide are needed.<sup>35</sup> Potassium-sparing diuretic spironolactone has been used successfully to treat heart failure,<sup>34</sup> but the insufficiency of data regarding its use in pregnancy means that cautious administration is warranted.

**Neurohormonal Blockade.** Angiotensin-modulating agents are considered first-line drugs for heart-failure management. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers improve survival but are contraindicated in pregnancy.<sup>34,36,37</sup> Also, since they are secreted in breast milk, breastfeeding must be stopped before commencing therapy.<sup>25</sup>

**Vasodilators.** Hydralazine is safe during pregnancy and is the primary vasodilator drug antepartum.<sup>25</sup> More severe cases warrant the use of intravenous nitroglycerin starting at 10 to 20 µg/min and continuing up to 200 µg/min.<sup>6</sup> Nitroprusside is not recommended because of the potential for cyanide toxicity.<sup>38</sup>

**Inotropic Agents.** Use of inotropic agents such as dopamine, dobutamine, and milrinone is warranted only in cases of severe low output, and the patient should be weaned from them as soon as she is hemodynamically stable.<sup>6</sup>

Levosimendan reduces pulmonary capillary wedge pressure and improves cardiac output of peripartum cardiomyopathy patients.<sup>39,40</sup> In a randomized trial,

**TABLE II.** Safety Profile of Drugs during Pregnancy and Lactation

Drug Name	Class	
	During Pregnancy	During Lactation
Hydrochlorothiazide	B <sup>a</sup>	AAP-compatible
Furosemide	C <sup>b</sup>	Continue feeding
Lisinopril	D <sup>c</sup>	Discontinue feeding
Losartan	D	Discontinue feeding
Hydralazine	C	AAP-compatible
Nitroglycerin	C	Unknown/caution
Nitroprusside	C	Unknown
Dopamine	C	Unknown
Dobutamine	B	Unknown
Milrinone	C	Unknown/caution
Epinephrine	C	Unknown
Norepinephrine	C	Unknown
Digoxin	C	AAP-compatible
Metoprolol	C	AAP-compatible
Carvedilol	C	Discontinue feeding
Amlodipine	C	Not recommended
Quinidine	C	Continue feeding
Procainamide	C	AAP-compatible
Warfarin	X <sup>d</sup>	AAP-compatible
Enoxaparin	B	Caution
Intravenous immunoglobulin	C	Unknown
Pentoxifylline	C	Discontinue feeding
Bromocriptine	B	Discontinue feeding

AAP = American Academy of Pediatrics

<sup>a</sup>Class B: Animal reproduction studies have failed to show a risk to the fetus, and there are no adequate and well-controlled studies in pregnant women; or animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

<sup>b</sup>Class C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in human beings, but potential benefits may warrant use of the drug in pregnant women despite risks.

<sup>c</sup>Class D: Positive evidence of human fetal risk has been shown by adverse-reaction data from investigational or marketing experience or studies in human beings, but potential benefits may warrant use of the drug in pregnant women despite risks.

<sup>d</sup>Class X: Studies in animals or human beings have shown fetal abnormalities or there is positive evidence of human fetal risk on the basis of adverse-reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.

however, 24 patients treated with levosimendan (0.1 µg/kg/min) for 24 hours (in addition to conventional therapy) showed no improvement.<sup>41</sup> Until adequate safety data are available, levosimendan should be avoided

antepartum and lactation should be held while using levosimendan. Since pregnant women are systemically vasoconstricted, vasopressors such as norepinephrine are usually avoided antepartum.

**Digoxin.** Digoxin, an inotropic and dromotropic agent, is safe to use during pregnancy.<sup>42,43</sup> The scarcity of available antepartum drug options and the increased hemodynamic loads during late pregnancy make digoxin an easy choice.

**$\beta$ -Blockers.**  $\beta$ -Blockers are crucial for long-term management of systolic dysfunction.<sup>34</sup> Although safe during pregnancy,  $\beta_1$ -selective blockers are preferred over nonselective  $\beta$ -blockers to avoid anti-tocolytic action induced by  $\beta_2$ -receptor blockade.<sup>44</sup> Carvedilol combined with  $\alpha$  blockade to restrict peripheral vasoconstriction has been shown to be effective in peripartum cardiomyopathy.<sup>4,45</sup> Patients receiving these drugs are weaned from them when ventricular function normalizes, within 6 to 12 months.

**Calcium Channel Blockers.** Dihydropyridines, such as amlodipine, have been shown to successfully reduce interleukin-6 levels in heart-failure patients,<sup>46,47</sup> but concomitant uterine hypoperfusion requires cautious use of these agents.<sup>46</sup>

### Arrhythmia Management

Atrial fibrillation is the most common arrhythmia in patients with peripartum cardiomyopathy.<sup>48</sup> Quinidine and procainamide are relatively safe to use in puerperium and are therefore considered first-line antiarrhythmics.<sup>49</sup> Digoxin can also be used as first-line therapy.<sup>43</sup> Refractory atrial fibrillation requires the placement of permanent pacemakers and implantable cardioverter-defibrillators.<sup>6</sup>

### Anticoagulation

Heart failure<sup>50</sup> and pregnancy<sup>51</sup> are independent risk factors for thromboembolism. The administration of low-molecular-weight heparin (LMWH) antepartum or heparin/LMWH and warfarin postpartum is recommended when the LVEF is  $<0.30$ .<sup>52,53</sup> Unfortunately, warfarin is teratogenic and must be avoided antepartum.<sup>53</sup>

Currently, there is no clear consensus on the appropriate duration of heart-failure drug therapy and its prophylactic role in subsequent pregnancies. The optimal approach is to follow the patient over time and gradually taper the drug doses over 6 to 12 months, when there is clinical and echocardiographic evidence of recovery. Complications and coexisting illnesses may require prolonged therapeutic support.

### Mechanical Circulatory Support and Transplantation

In severe cases of peripartum cardiomyopathy, mechanical circulatory support and even heart transplantation

may be needed. Both intra-aortic balloon pumps and LV assist devices (LVADs) have been used as bridges to transplantation.<sup>6,54</sup> Peripartum cardiomyopathy has resolved in some patients so treated with LVADs.<sup>55</sup> Because peripartum cardiomyopathy can resolve within 3 to 6 months postpartum,<sup>27</sup> LVADs can also serve as a bridge to recovery in cases of fulminant peripartum cardiomyopathy. In recent years, bridging to recovery via prolonged circulatory support has helped to dramatically decrease the percentage of peripartum cardiomyopathy patients requiring transplantation, from 33%<sup>56</sup> to 4%–7%.<sup>5</sup> Yet, few studies have looked into heart-transplant outcomes in peripartum cardiomyopathy patients and compared them with transplant outcomes in idiopathic DCM patients.<sup>56–58</sup> The potential for organ rejection in peripartum cardiomyopathy is high due to the increased prevalence of autoimmune mechanisms. Some investigators have suggested, interestingly, that transplantation at a younger age and closer to onset can improve prognosis.<sup>25</sup> Meanwhile, no data regarding the risk of rejection in subsequent pregnancies are available.<sup>59</sup>

### Targeted Therapy

**Immunosuppressive Drugs.** Immunosuppressive drug therapy for peripartum cardiomyopathy has not been universally successful.<sup>20,60</sup> Empiric immunosuppressive therapy is not recommended because myocarditis is not present in all cases and because associated adverse events may occur.<sup>20</sup> However, it remains an option when active myocarditis has been confirmed by endomyocardial biopsy.<sup>60</sup>

**Intravenous Immunoglobulin.** Intravenous immunoglobulin therapy is a promising approach to improving cardiac function. In a small retrospective study of women with peripartum cardiomyopathy and an LVEF of  $<0.40$ , the improvement in patients treated with intravenous immunoglobulin was greater than in control participants (26% vs 13%,  $P=0.042$ ).<sup>61</sup> These results, however, have not yet been replicated.<sup>60</sup>

**Pentoxifylline.** In a nonrandomized trial of peripartum cardiomyopathy, 29 patients were administered pentoxifylline 400 mg 3 times daily, while 30 control patients received standard care.<sup>62</sup> At 6 months, the pentoxifylline-treated group showed a clear survival benefit over the control group (1 death vs 8 deaths). This survival benefit was attributed to the TNF- $\alpha$ , CRP, and Fas/Apo-1 reducing actions of pentoxifylline.<sup>62</sup> Additional randomized trials to confirm these findings must be performed before broader clinical adoption.<sup>62</sup>

**Bromocriptine.** In a pilot study in peripartum cardiomyopathy, 10 patients were administered the prolactin inhibitor bromocriptine at a dose of 2.5 mg twice daily for 2 weeks and then 2.5 mg twice daily for 4 weeks, in addition to receiving standard care, while 10 control patients received only standard care.<sup>6</sup> The bromocriptine group had both better survival (1 vs 4 deaths) and

**TABLE III.** Major Studies That Have Investigated Prognosis in Peripartum Cardiomyopathy

Authors	Study Type	No. Pts.	Mean Age, yr	Enrollment Period	Mortality Rate, %	Findings
Karaye KM, et al. <sup>65</sup>	Cross-sectional	55	26	2008–2009	—	Peripartum cardiomyopathy associated with decreased QRS interval and decreased atrial arrhythmias. Mean age of peripartum cardiomyopathy lower than in other causes of cardiomyopathy.
Goland S, et al. <sup>66</sup>	Retrospective	182	29	2009*	28	Major adverse events are more common in nonwhites and with LVEF $\leq 0.25$ .
Gentry MB, et al. <sup>10</sup>	Retrospective	28	25	2003–2008	—	Black women had 15.7% higher relative risk of peripartum cardiomyopathy than nonblacks. Other risk factors include hypertension history, >2 previous pregnancies, and unmarried status.
Duran N, et al. <sup>67</sup>	Retrospective and prospective	33	33	1995–2007	30	LVEF >0.27 and LVESD $\leq 5.5$ cm may predict LV recovery.
Safirstein JG, et al. <sup>68</sup>	Survey	55	32	2005–2007	—	Gestational hypertension positive, LVEF $\leq 0.35$ at diagnosis, breastfeeding history, and postpartum diagnosis are associated with peripartum cardiomyopathy recovery.
Hasan JA, et al. <sup>69</sup>	Retrospective	32	32	2003–2007	—	Chronic hypertension, long-term tocolysis, pre-eclampsia, and multiple pregnancies were risk factors for peripartum cardiomyopathy.
Hu CL, et al. <sup>33</sup>	Prospective	106	28	2007*	—	LV dysfunction more persistent in pts with cardiac troponin levels >0.04 ng/mL.
Brar SS, et al. <sup>70</sup>	Retrospective	60	34	1996–2005	3.3	Peripartum cardiomyopathy incidence highest in black and lowest in Hispanic populations.
Sliwa K, et al. <sup>71</sup>	Prospective	80	30	2005*	10 (6 mo), 28 (2 yr)	Peripartum cardiomyopathy mortality rate remains high after 6 mo.
Sliwa K, et al. <sup>13</sup>	Prospective	100	32	2003–2005	15	C-reactive protein level correlated with LVESD and inversely with LVEF. High Fas/Apo-1 and low mean LVEF at presentation predicted death.
Fett JD, et al. <sup>8</sup>	Prospective	92	32	2000–2005	15	Mean LVEF and fractional shortening at diagnosis higher in recovered pts than in unrecovered pts.
Elkayam U, et al. <sup>5</sup>	Survey	100	31	2005	9	Subsequent pregnancy in peripartum cardiomyopathy pts is associated with decrease in LV function.
Isezuo SA and Abubakar SA <sup>48</sup>	Cross-sectional	65	28	2003–2005	12	Peripartum cardiomyopathy outcome influenced by cardiothoracic index, LVEF, and diastolic pressure. Patients who died had lower diastolic pressure and higher cardiothoracic index.
Modi KA, et al. <sup>72</sup>	Retrospective	44	25	1992–2003	16	In black pts, LV function and recovery rates comparable to those in studies reported from Haiti and South Africa.
Mielniczuk LM, et al. <sup>73</sup>	Retrospective	171	30	1990–2002	1.36–2.05	Peripartum cardiomyopathy pts more likely to be older, black, and with pregnancy-associated hypertensive disorder.
Fett JD, et al. <sup>74</sup>	Retrospective and prospective	47	32	1994–2001	14	Very high incidence of peripartum cardiomyopathy in Haiti (1 case/400 live births).
Chapa JB, et al. <sup>75</sup>	Retrospective	32	27	1988–2001	10	LV fractional shortening <20% and LVESD $\geq 6$ cm at diagnosis is associated with 3-fold risk of poor LV recovery.
Felker GM, et al. <sup>76</sup>	—	51	29	1983–1998	6	Patients with peripartum cardiomyopathy have better prognosis than do pts with other forms of cardiomyopathy.
Sliwa K, et al. <sup>77</sup>	Prospective	29	29	1996–1997	28	TNF- $\alpha$ , IL-6, and Fas/Apo-1 levels are elevated in peripartum cardiomyopathy pts. Fas/Apo-1 levels were higher in nonsurvivors.
Witlin AG, et al. <sup>78</sup>	Prospective	28	—	1986–1994	18	Commonly associated disorders included preeclampsia of chronic hypertension (19 pts), alcohol abuse (2), positive family history (2), and multiple tocolytic therapy (2).
Desai D, et al. <sup>79</sup>	Retrospective	99	29	1986–1989	14	Increasing age and multiparity did not favor adverse outcomes, but late presentation predicted adverse outcomes.
Carvalho A, et al. <sup>80</sup>	Prospective	19	26	1982–1988	16	Death is predicted by increased LVESD and late onset of symptoms.

Fas/Apo-1 = Fas/apoptosis antigen 1; IL-6 = interleukin-6; LV = left ventricular; LVESD = left ventricular end-diastolic diameter; LVEF = left ventricular ejection fraction; LVESD = left ventricular end-systolic diameter; Pts = patients; TNF- $\alpha$  = tumor necrosis factor- $\alpha$

\*Year in which recruitment began.

greater LVEF recovery (from 0.27 at baseline [both groups] to 0.58 [bromocriptine] vs 0.36 [control] at 6 mo).<sup>63</sup> Multicenter, randomized, blinded trials to confirm these findings and establish bromocriptine's safety profile in pregnancy must be performed before bromocriptine enters routine clinical use.<sup>63</sup>

## Prognosis

Recovery from peripartum cardiomyopathy is defined as recovery of LVEF to  $\geq 0.50$  or improvement by  $>0.20$ . As already mentioned, recovery usually occurs between 3 and 6 months postpartum, but might occur as late as 48 months postpartum.<sup>27</sup> Delayed diagnosis,<sup>64</sup> higher NYHA functional class, black ethnicity,<sup>10</sup> LV thrombus,<sup>64</sup> multiparity,<sup>11</sup> and coexisting medical illnesses are associated with delayed recovery. In a 2-year, long-term follow-up study in 123 peripartum cardiomyopathy patients, mean LVEF increased from 0.28 to 0.46, and in just over half of these cases reached  $>0.50$ .<sup>5</sup> Furthermore, recovery was greatest when baseline LVEF was  $>0.30$  and impaired when baseline LV end-diastolic diameter (LVEDD) was  $>5.6$  cm<sup>5</sup>; patients exhibiting low levels of recovery often required a heart transplant.<sup>64</sup> Also, high troponin levels at baseline were predictive of poor LVEF at 6 months.<sup>3</sup> Inflammatory markers such as CRP correlate positively with baseline LVEDD and LVESD but negatively with LVEF in patients with peripartum cardiomyopathy<sup>13</sup> (Table III<sup>5,8,10,13,33,48,65-80</sup>).

The estimated mortality rate associated with peripartum cardiomyopathy in the United States is 6% to 10%.<sup>81</sup> Death usually occurs within 30 days but has occurred later as well.<sup>11</sup> The estimated 6-month and 2-year mortality rates in South Africa are 10% and 28%, respectively.<sup>6</sup> It is of interest that nonsurvivors have higher Fas/Apo-1 levels.<sup>13</sup>

Even after complete recovery from peripartum cardiomyopathy, the risk of recurrence in subsequent pregnancies remains high, and LVEF, once improved, can worsen again.<sup>6</sup> In a study of 44 women who recovered from peripartum cardiomyopathy and subsequently became pregnant, LVEF deterioration was more frequent in those with partial recovery than in those with complete recovery (44% vs 21%).<sup>82</sup> In a prospective study of 61 post-peripartum cardiomyopathy pregnancies, relapse occurred more often in patients who had a prior LVEF  $<0.55$  than in those who had a prior LVEF  $\geq 0.55$  (46% vs 17%).<sup>28</sup> Generally, post-peripartum cardiomyopathy pregnancies are marked by a decline in LVEF.<sup>83</sup> Exercise stress echocardiography to estimate contractile reserve can uncover subtle residual cardiac dysfunction that might be exacerbated during a pregnancy.<sup>28</sup> At present, it is difficult to predict outcomes of a post-peripartum cardiomyopathy pregnancy, and current peripartum cardiomyopathy guidelines advise against future pregnancies.<sup>6</sup>

## Conclusion

Peripartum cardiomyopathy is a rare but serious condition of unknown cause that affects childbearing women. Diagnosis of peripartum cardiomyopathy requires heightened awareness among multidisciplinary patient care teams and a high degree of suspicion. Management of peripartum cardiomyopathy should aim first at improving heart-failure symptoms through conventional therapies, and then at administering targeted therapies. Targeted therapies (for example, intravenous immunoglobulin, pentoxifylline, and bromocriptine) show promise but need further clinical evaluation before they can be widely adopted. The prognosis is best when peripartum cardiomyopathy is diagnosed and treated early. Fortunately, despite a high risk of recurrence in subsequent pregnancies, many patients with peripartum cardiomyopathy recover within 3 to 6 months of disease onset. A large multicenter, prospective randomized trial is currently needed to evaluate the incidence, the pathophysiology (which would include setting up a biorepository for genetic and translational studies), and the current therapies for peripartum cardiomyopathy.

## References

1. Demakis JG, Rahimtoola SH. Peripartum cardiomyopathy. *Circulation* 1971;44(5):964-8.
2. Manolio TA, Baughman KL, Rodeheffer R, Pearson TA, Bristow JD, Michels VV, et al. Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop). *Am J Cardiol* 1992;69(17):1458-66.
3. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. *Cell* 2007;128(3):589-600.
4. Pearson GD, Veille JC, Rahimtoola S, Hsia J, Oakley CM, Hosenpud JD, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. *JAMA* 2000;283(9):1183-8.
5. Elkayam U, Akhter MW, Singh H, Khan S, Bitar F, Hameed A, Shotan A. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. *Circulation* 2005;111(16):2050-5.
6. Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. *Eur J Heart Fail* 2010;12(8):767-78.
7. Sanderson JE, Adesanya CO, Anjorin FI, Parry EH. Postpartum cardiac failure—heart failure due to volume overload? *Am Heart J* 1979;97(5):613-21.
8. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. *Mayo Clin Proc* 2005;80(12):1602-6.

9. Sliwa K, Damasceno A, Mayosi BM. Epidemiology and etiology of cardiomyopathy in Africa. *Circulation* 2005;112(23):3577-83.
10. Gentry MB, Dias JK, Luis A, Patel R, Thornton J, Reed GL. African-American women have a higher risk for developing peripartum cardiomyopathy. *J Am Coll Cardiol* 2010;55(7):654-9.
11. Homans DC. Peripartum cardiomyopathy. *N Engl J Med* 1985;312(22):1432-7.
12. Whitehead SJ, Berg CJ, Chang J. Pregnancy-related mortality due to cardiomyopathy: United States, 1991-1997. *Obstet Gynecol* 2003;102(6):1326-31.
13. Sliwa K, Forster O, Libhaber E, Fett JD, Sundstrom JB, Hilfiker-Kleiner D, Ansari AA. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. *Eur Heart J* 2006;27(4):441-6.
14. Burton GJ, Jauniaux E. Oxidative stress. *Best Pract Res Clin Obstet Gynaecol* 2011;25(3):287-99.
15. Melvin KR, Richardson PJ, Olsen EG, Daly K, Jackson G. Peripartum cardiomyopathy due to myocarditis. *N Engl J Med* 1982;307(12):731-4.
16. Bhakta P, Biswas BK, Banerjee B. Peripartum cardiomyopathy: review of the literature. *Yonsei Med J* 2007;48(5):731-47.
17. Bultmann BD, Klingel K, Nabauer M, Wallwiener D, Kandolf R. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. *Am J Obstet Gynecol* 2005;193(2):363-5.
18. Rizeq MN, Rickenbacher PR, Fowler MB, Billingham ME. Incidence of myocarditis in peripartum cardiomyopathy. *Am J Cardiol* 1994;74(5):474-7.
19. Ravikishore AG, Kaul UA, Sethi KK, Khalilullah M. Peripartum cardiomyopathy: prognostic variables at initial evaluation. *Int J Cardiol* 1991;32(3):377-80.
20. Midei MG, DeMent SH, Feldman AM, Hutchins GM, Baughman KL. Peripartum myocarditis and cardiomyopathy. *Circulation* 1990;81(3):922-8.
21. Ansari AA, Fett JD, Carraway RE, Mayne AE, Onlamoon N, Sundstrom JB. Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. *Clin Rev Allergy Immunol* 2002;23(3):301-24.
22. Lapaire O, Hosli I, Zanetti-Daellenbach R, Huang D, Jaeggi C, Garfield-Mergenthaler S, et al. Impact of fetal-maternal microchimerism on women's health—a review. *J Matern Fetal Neonatal Med* 2007;20(1):1-5.
23. van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, van der Werf R, Jongbloed JD, Paulus WJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. *Circulation* 2010;121(20):2169-75.
24. Morales A, Painter T, Li R, Siegfried JD, Li D, Norton N, Hershberger RE. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. *Circulation* 2010;121(20):2176-82.
25. Lampert MB, Lang RM. Peripartum cardiomyopathy. *Am Heart J* 1995;130(4):860-70.
26. Demakis JG, Rahimtoola SH, Sutton GC, Meadows WR, Szanto PB, Tobin JR, Gunnar RM. Natural course of peripartum cardiomyopathy. *Circulation* 1971;44(6):1053-61.
27. Fett JD, Sannon H, Thelisma E, Sprunger T, Suresh V. Recovery from severe heart failure following peripartum cardiomyopathy. *Int J Gynaecol Obstet* 2009;104(2):125-7.
28. Fett JD, Fristoe KL, Welsh SN. Risk of heart failure relapse in subsequent pregnancy among peripartum cardiomyopathy mothers. *Int J Gynaecol Obstet* 2010;109(1):34-6.
29. Chen MM, Coakley FV, Kaimal A, Laros RK Jr. Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation. *Obstet Gynecol* 2008;112(2 Pt 1):333-40.
30. Leurent G, Baruteau AE, Larralde A, Ollivier R, Schleich JM, Boulmier D, et al. Contribution of cardiac MRI in the comprehension of peripartum cardiomyopathy pathogenesis. *Int J Cardiol* 2009;132(3):e91-3.
31. Veille JC. Peripartum cardiomyopathies: a review. *Am J Obstet Gynecol* 1984;148(6):805-18.
32. Forster O, Hilfiker-Kleiner D, Ansari AA, Sundstrom JB, Libhaber E, Tshani W, et al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. *Eur J Heart Fail* 2008;10(9):861-8.
33. Hu CL, Li YB, Zou YG, Zhang JM, Chen JB, Liu J, et al. Troponin T measurement can predict persistent left ventricular dysfunction in peripartum cardiomyopathy. *Heart* 2007;93(4):488-90.
34. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation [published erratum appears in *Circulation* 2010;121(12):e258]. *Circulation* 2009;119(14):e391-479.
35. Lindheimer MD, Katz AI. Sodium and diuretics in pregnancy. *N Engl J Med* 1973;288(17):891-4.
36. Lavoratti G, Seracini D, Fiorini P, Cocchi C, Materassi M, Donzelli G, Pela I. Neonatal anuria by ACE inhibitors during pregnancy. *Nephron* 1997;76(2):235-6.
37. Alwan S, Polifka JE, Friedman JM. Angiotensin II receptor antagonist treatment during pregnancy. *Birth Defects Res A Clin Mol Teratol* 2005;73(2):123-30.
38. Palmer RF, Lasseter KC. Drug therapy. Sodium nitropruside. *N Engl J Med* 1975;292(6):294-7.
39. Benezet-Mazuecos J, de la Hera J. Peripartum cardiomyopathy: a new successful setting for levosimendan. *Int J Cardiol* 2008;123(3):346-7.
40. Benlolo S, Lefoll C, Katchatouryan V, Payen D, Mebazaa A. Successful use of levosimendan in a patient with peripartum cardiomyopathy. *Anesth Analg* 2004;98(3):822-4.
41. Biteker M, Duran NE, Kaya H, Gunduz S, Tanboga HI, Gokdeniz T, et al. Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial. *Clin Res Cardiol* 2011;100(7):571-7.
42. Widerhorn J, Rubin JN, Frishman WH, Elkayam U. Cardiovascular drugs in pregnancy. *Cardiol Clin* 1987;5(4):651-74.
43. Joglar JA, Page RL. Treatment of cardiac arrhythmias during pregnancy: safety considerations. *Drug Saf* 1999;20(1):85-94.
44. Easterling TR, Carr DB, Brateng D, Diederichs C, Schmucker B. Treatment of hypertension in pregnancy: effect of atenolol on maternal disease, preterm delivery, and fetal growth. *Obstet Gynecol* 2001;98(3):427-33.
45. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohaci P, et al. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med* 2001;344(22):1651-8.
46. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. *N Engl J Med* 1996;335(15):1107-14.
47. Mohler ER 3rd, Sorensen LC, Ghali JK, Schocken DD, Willis PW, Bowers JA, et al. Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation. *J Am Coll Cardiol* 1997;30(1):35-41.



48. Isezuo SA, Abubakar SA. Epidemiologic profile of peripartum cardiomyopathy in a tertiary care hospital. *Ethn Dis* 2007;17(2):228-33.
49. Ferrero S, Colombo BM, Ragni N. Maternal arrhythmias during pregnancy. *Arch Gynecol Obstet* 2004;269(4):244-53.
50. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. *Circulation* 1993;87(6 Suppl):VI94-101.
51. Refuerzo JS, Hechtman JL, Redman ME, Whitty JE. Venous thromboembolism during pregnancy. Clinical suspicion warrants evaluation. *J Reprod Med* 2003;48(10):767-70.
52. Nelson-Piercy C, Letsky EA, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. *Am J Obstet Gynecol* 1997;176(5):1062-8.
53. Howie PW. Anticoagulants in pregnancy. *Clin Obstet Gynaecol* 1986;13(2):349-63.
54. Gevaert S, Van Belleghem Y, Bouchez S, Herck I, De Somer F, De Block Y, et al. Acute and critically ill peripartum cardiomyopathy and 'bridge to' therapeutic options: a single center experience with intra-aortic balloon pump, extra corporeal membrane oxygenation and continuous-flow left ventricular assist devices. *Crit Care* 2011;15(2):R93.
55. Zimmerman H, Bose R, Smith R, Copeland JG. Treatment of peripartum cardiomyopathy with mechanical assist devices 1211-7.
56. Keogh A, Macdonald P, Spratt P, Marshman D, Larbalestier R, Kaan A. Outcome in peripartum cardiomyopathy after heart transplantation. *J Heart Lung Transplant* 1994;13(2):202-7.
57. Rickenbacher PR, Rizeq MN, Hunt SA, Billingham ME, Fowler MB. Long-term outcome after heart transplantation for peripartum cardiomyopathy. *Am Heart J* 1994;127(5):1318-23.
58. Aziz TM, Burgess MI, Acladiou NN, Campbell CS, Rahman AN, Yonan N, Deiraniya AK. Heart transplantation for peripartum cardiomyopathy: a report of three cases and a literature review. *Cardiovasc Surg* 1999;7(5):565-7.
59. Branch KR, Wagoner LE, McGrory CH, Mannion JD, Radoski JS, Moritz MJ, et al. Risks of subsequent pregnancies on mother and newborn in female heart transplant recipients. *J Heart Lung Transplant* 1998;17(7):698-702.
60. Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. *N Engl J Med* 1995;333(5):269-75.
61. Bozkurt B, Villaneuva FS, Holubkov R, Tokarczyk T, Alvarez RJ Jr, MacGowan GA, et al. Intravenous immune globulin in the therapy of peripartum cardiomyopathy. *J Am Coll Cardiol* 1999;34(1):177-80.
62. Sliwa K, Skudicky D, Candy G, Bergemann A, Hopley M, Sareli P. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. *Eur J Heart Fail* 2002;4(3):305-9.
63. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. *Circulation* 2010;121(13):1465-73.
64. Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. *Am Heart J* 2006;152(3):509-13.
65. Karaye KM, Sai'du H, Habib AG. Peripartum and other cardiomyopathies in a Nigerian adult population. *Int J Cardiol* 2011;147(2):342-3.
66. Goland S, Modi K, Bitar F, Janmohamed M, Mirocha JM, Czer LS, et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. *J Card Fail* 2009;15(8):645-50.
67. Duran N, Gunes H, Duran I, Biteker M, Ozkan M. Predictors of prognosis in patients with peripartum cardiomyopathy. *Int J Gynaecol Obstet* 2008;101(2):137-40.
68. Safirstein JG, Ro AS, Grandhi S, Wang L, Fett JD, Staniloae C. Predictors of left ventricular recovery in a cohort of peripartum cardiomyopathy patients recruited via the internet. *Int J Cardiol* 2012;154(1):27-31. Epub 2010 Sep 21.
69. Hasan JA, Qureshi A, Ramejo BB, Kamran A. Peripartum cardiomyopathy characteristics and outcome in a tertiary care hospital. *J Pak Med Assoc* 2010;60(5):377-80.
70. Brar SS, Khan SS, Sandhu GK, Jorgensen MB, Parikh N, Hsu JW, Shen AY. Incidence, mortality, and racial differences in peripartum cardiomyopathy. *Am J Cardiol* 2007;100(2):302-4.
71. Sliwa K, Forster O, Tibazarwa K, Libhaber E, Becker A, Yip A, Hilfiker-Kleiner D. Long-term outcome of peripartum cardiomyopathy in a population with high seropositivity for human immunodeficiency virus. *Int J Cardiol* 2011;147(2):202-8.
72. Modi KA, Illum S, Jariatul K, Caldito G, Reddy PC. Poor outcome of indigent patients with peripartum cardiomyopathy in the United States. *Am J Obstet Gynecol* 2009;201(2):171.e1-5.
73. Mielniczuk LM, Williams K, Davis DR, Tang AS, Lemery R, Green MS, et al. Frequency of peripartum cardiomyopathy. *Am J Cardiol* 2006;97(12):1765-8.
74. Fett JD, Carraway RD, Dowell DL, King ME, Pierre R. Peripartum cardiomyopathy in the Hospital Albert Schweitzer District of Haiti. *Am J Obstet Gynecol* 2002;186(5):1005-10.
75. Chapa JB, Heiberger HB, Weinert L, Decara J, Lang RM, Hibbard JU. Prognostic value of echocardiography in peripartum cardiomyopathy. *Obstet Gynecol* 2005;105(6):1303-8.
76. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemenson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. *N Engl J Med* 2000;342(15):1077-84.
77. Sliwa K, Skudicky D, Bergemann A, Candy G, Puren A, Sareli P. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. *J Am Coll Cardiol* 2000;35(3):701-5.
78. Witlin AG, Mabie WC, Sibai BM. Peripartum cardiomyopathy: an ominous diagnosis. *Am J Obstet Gynecol* 1997;176(1 Pt 1):182-8.
79. Desai D, Moodley J, Naidoo D. Peripartum cardiomyopathy: experiences at King Edward VIII Hospital, Durban, South Africa and a review of the literature. *Trop Doct* 1995;25(3):118-23.
80. Carvalho A, Brandao A, Martinez EE, Alexopoulos D, Lima VC, Andrade JL, Ambrose JA. Prognosis in peripartum cardiomyopathy. *Am J Cardiol* 1989;64(8):540-2.
81. Felker GM, Jaeger CJ, Klodas E, Thiemann DR, Hare JM, Hruban RH, et al. Myocarditis and long-term survival in peripartum cardiomyopathy. *Am Heart J* 2000;140(5):785-91.
82. Elkayam U, Tummala PP, Rao K, Akhter MW, Karaalp IS, Wani OR, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy [published erratum appears in *N Engl J Med* 2001;345(7):552]. *N Engl J Med* 2001;344(21):1567-71.
83. Mandal D, Mandal S, Mukherjee D, Biswas SC, Maiti TK, Chattopadhyaya N, et al. Pregnancy and subsequent pregnancy outcomes in peripartum cardiomyopathy. *J Obstet Gynaecol Res* 2011;37(3):222-7.